Pharmaceutical

SY-001 by CellOrigin Technology (Hangzhou) for Solid Tumor: Likelihood of Approval

SY-001 is under clinical development by CellOrigin Technology (Hangzhou) and currently in Phase I for Solid Tumor.

Feb 20, 2024 - 18:00
SY-001 is under clinical development by CellOrigin Technology (Hangzhou) and currently in Phase I for Solid Tumor.
Read the original article

Tags:

Previous Article

RioDerm-001 by Rion for Diabetic Foot Ulcers: Likelihood of Approval

Next Article

Denali-Sanofi’s ALS Candidate Falls Short in Mid-Stage Study

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Europe issues maximum antitrust fine of $475 million to Illumina over Grail deal

STAT+: Europe issues maximum antitrust fine of $475 mil...

Jul 12, 2023

Opinion: Why the debate over proposed nursing home staff minimums is particularly unproductive

Opinion: Why the debate over proposed nursing home staf...

Feb 5, 2024

Novartis acquires Chinook for $3.2bn to boost kidney disease pipeline

Novartis acquires Chinook for $3.2bn to boost kidney di...

Aug 14, 2023